Exparel 1.3% 20ML 10S
Ended Awarded Last action
- Contract number
- SPE2DR26FHYV7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,269
Award facts
- Contract value 100% obligated
- $10,269.28 Current and potential, with all options
- Completion date
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency has issued a delivery order valued at $10,269.28 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for EXPAREL 1.3% (20ML, 10 units). This firm fixed-price delivery order, issued on January 20, 2026, represents a supply of liposomal bupivacaine, a specialty surgical anesthetic product used in perioperative pain management. The award carries no set-aside designation, reflecting DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The place of performance is Park Ridge, Illinois, with an ultimate completion date of January 20, 2026.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to streamline pharmaceutical supply to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group holds a single-award IDC with a $499.99 billion ceiling value and a completion date of December 31, 2036, positioning the company as a critical regional pharmaceutical supplier for military medical operations. The company's extensive product portfolio encompasses branded and generic pharmaceuticals, biologics, vaccines, and specialty surgical products, enabling it to fulfill diverse medical supply requirements across the global Defense Department healthcare system.
Quick answers
Who was awarded contract SPE2DR26FHYV7?
SPE2DR26FHYV7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FHYV7 worth?
The government has obligated $10,269 on SPE2DR26FHYV7.
Is contract SPE2DR26FHYV7 an order under another contract?
Yes. SPE2DR26FHYV7 is a delivery order under SPE2DR25D9762, an indefinite delivery contract.
Was contract SPE2DR26FHYV7 competed?
The extent of competition for SPE2DR26FHYV7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award